• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

地拉罗司与一名镰状细胞贫血患者的肝衰竭和死亡相关，该患者的 基因中 -1774delG 多态性为纯合子。

Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the -1774delG polymorphism in the gene.

作者信息

Braga Caroline C B, Benites Bruno Deltreggia, de Albuquerque Dulcineia M, Alvarez Marisa C, Seva-Pereira Tiago, Duarte Bruno K L, Costa Fernando F, Gilli Simone C O, Saad Sara T O

机构信息

Hematology and Transfusion Medicine Center University of Campinas Campinas Brazil.

Unit of Liver Transplantation University of Campinas Campinas Brazil.

出版信息

Clin Case Rep. 2017 Jun 15;5(8):1218-1221. doi: 10.1002/ccr3.1040. eCollection 2017 Aug.

DOI:10.1002/ccr3.1040
PMID:28781827
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5538070/
Abstract

This manuscript describes the case of a patient with sickle cell anemia who died of fulminant hepatitis after therapy with the iron chelator Deferasirox. The patient was homozygous for the -1774delG polymorphism in the gene, which raises the concern about the use of hepatotoxic drugs in this specific context.

摘要

本手稿描述了一例镰状细胞贫血患者在接受铁螯合剂地拉罗司治疗后死于暴发性肝炎的病例。该患者基因中的-1774delG多态性为纯合子，这引发了在这种特定情况下使用肝毒性药物的担忧。

相似文献

1
Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the -1774delG polymorphism in the gene.地拉罗司与一名镰状细胞贫血患者的肝衰竭和死亡相关，该患者的 基因中 -1774delG 多态性为纯合子。
Clin Case Rep. 2017 Jun 15;5(8):1218-1221. doi: 10.1002/ccr3.1040. eCollection 2017 Aug.
2
Iron chelator deferasirox rescued mice from Fas-induced fulminant hepatitis.铁螯合剂地拉罗司可拯救 Fas 诱导的暴发性肝炎小鼠。
Hepatol Res. 2011 Jul;41(7):660-7. doi: 10.1111/j.1872-034X.2011.00821.x.
3
The challenges of handling deferasirox in sickle cell disease patients older than 40 years.在40岁以上镰状细胞病患者中使用地拉罗司的挑战。
Hematology. 2019 Dec;24(1):596-600. doi: 10.1080/16078454.2019.1657667.
4
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.地拉罗司与去铁胺治疗镰状细胞病输血性铁过载的随机对照研究
Br J Haematol. 2007 Feb;136(3):501-8. doi: 10.1111/j.1365-2141.2006.06455.x.
5
Deferasirox for managing transfusional iron overload in people with sickle cell disease.地拉罗司用于治疗镰状细胞病患者的输血性铁过载。
Cochrane Database Syst Rev. 2010 Aug 4(8):CD007477. doi: 10.1002/14651858.CD007477.pub2.
6
Deferasirox (Exjade) for the treatment of iron overload.地拉罗司（恩瑞格）用于治疗铁过载。
Acta Haematol. 2009;122(2-3):165-73. doi: 10.1159/000243801. Epub 2009 Nov 10.
7
Deferasirox effectively decreases iron burden in patients with double heterozygous HbS/β-thalassemia.地拉罗司可有效降低双重杂合子 HbS/β-地中海贫血患者的铁负荷。
Ann Hematol. 2011 Jan;90(1):11-5. doi: 10.1007/s00277-010-1029-7. Epub 2010 Jul 27.
8
Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.两年疗效和安全性分析：去铁酮治疗镰状细胞贫血患者输血铁过载。
Acta Haematol. 2012;128(2):113-8. doi: 10.1159/000338560. Epub 2012 Jun 30.
9
MRP2 haplotypes confer differential susceptibility to toxic liver injury.多药耐药相关蛋白2单倍型赋予对中毒性肝损伤的不同易感性。
Pharmacogenet Genomics. 2007 Jun;17(6):403-15. doi: 10.1097/01.fpc.0000236337.41799.b3.
10
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.比较去铁酮与去铁胺在镰状细胞病中的疗效和安全性：包括药代动力学和同时使用羟基脲的两年结果。
Am J Hematol. 2013 Dec;88(12):1068-73. doi: 10.1002/ajh.23569. Epub 2013 Sep 19.

引用本文的文献

1
Extracorporeal Blood Purification Therapy to Deal a Deferasirox Induced Life-Threatening Hepatic Encephalopathy in a Septic Child With Sickle-Cell Disease: A Case Report.体外血液净化疗法治疗镰状细胞病败血症患儿中地拉罗司诱发的危及生命的肝性脑病：一例报告
J Clin Apher. 2025 Jun;40(3):e70032. doi: 10.1002/jca.70032.
2
Drug-induced liver injury from Deferasirox in a pediatric patient with hereditary spherocytosis: A case report.一名遗传性球形红细胞增多症儿科患者使用地拉罗司后发生药物性肝损伤：病例报告
JPGN Rep. 2024 Dec 16;6(1):56-59. doi: 10.1002/jpr3.12155. eCollection 2025 Feb.
3
Case report: Acute liver failure during deferasirox therapy and the potential role of pharmacogenetics.

本文引用的文献

1
Pharmacogenetic study of deferasirox, an iron chelating agent.铁螯合剂地拉罗司的药物遗传学研究。
PLoS One. 2013 May 30;8(5):e64114. doi: 10.1371/journal.pone.0064114. Print 2013.
2
The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.儿童镰状细胞病的一级卒中预防的临床效果和成本效益：系统评价和经济评估。
Health Technol Assess. 2012;16(43):1-129. doi: 10.3310/hta16430.
3
Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey.
病例报告：地拉罗司治疗期间的急性肝衰竭及药物遗传学的潜在作用。
Front Pharmacol. 2024 Oct 23;15:1477755. doi: 10.3389/fphar.2024.1477755. eCollection 2024.
4
Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.预测非酒精性脂肪性肝炎患者药物药代动力学的改变及药物不良反应风险
Acta Pharm Sin B. 2023 Jan;13(1):1-28. doi: 10.1016/j.apsb.2022.08.018. Epub 2022 Aug 28.
5
Role and Regulation of Hepatobiliary ATP-Binding Cassette Transporters during Chemical-Induced Liver Injury.化学性肝损伤中肝胆 ATP 结合盒转运蛋白的作用与调控。
Drug Metab Dispos. 2022 Oct;50(10):1376-1388. doi: 10.1124/dmd.121.000450. Epub 2022 Aug 1.
6
Questioning Established Theories and Treatment Methods Related to Iron and Other Metal Metabolic Changes, Affecting All Major Diseases and Billions of Patients.质疑与铁及其他金属代谢变化相关的既定理论和治疗方法，影响所有主要疾病和数十亿患者。
Int J Mol Sci. 2022 Jan 25;23(3):1364. doi: 10.3390/ijms23031364.
7
Differences between the European Union and United States of America in Drug Regulatory Affairs Affect Global Patient Safety Standards and Public Health Awareness: The Case of Deferasirox and Other Iron Chelating Drugs.欧盟与美国在药品监管事务上的差异影响全球患者安全标准和公众健康意识：以地拉罗司及其他铁螯合剂药物为例
Medicines (Basel). 2021 Jul 7;8(7):36. doi: 10.3390/medicines8070036.
8
Artesunate induces ER-derived-ROS-mediated cell death by disrupting labile iron pool and iron redistribution in hepatocellular carcinoma cells.青蒿琥酯通过破坏肝细胞癌细胞中不稳定铁池和铁再分布，诱导内质网衍生的活性氧介导的细胞死亡。
Am J Cancer Res. 2021 Mar 1;11(3):691-711. eCollection 2021.
镰状细胞病患者输血治疗及铁过载的处理方法：一项国际调查结果
Pediatr Hematol Oncol. 2011 Feb;28(1):37-42. doi: 10.3109/08880018.2010.505497. Epub 2010 Jul 30.
4
Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion.镰状细胞贫血血管阻塞性危象疼痛管理：共识意见。
Clin Appl Thromb Hemost. 2010 Aug;16(4):365-76. doi: 10.1177/1076029609352661. Epub 2010 Jun 7.
5
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.通过铁摄入量和血清铁蛋白调整铁螯合治疗：前瞻性 EPIC 研究中 1744 例输血依赖型贫血患者应用地拉罗司。
Haematologica. 2010 Apr;95(4):557-66. doi: 10.3324/haematol.2009.014696. Epub 2009 Nov 30.
6
Update on toxicity and efficacy aspects of treatment with deferasirox and its implication on the morbidity and mortality of transfused iron loaded patients.地拉罗司治疗的毒性和疗效方面的最新进展及其对输血性铁过载患者发病率和死亡率的影响
Expert Opin Drug Saf. 2008 Nov;7(6):645-6. doi: 10.1517/14740330802137479.
7
Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats.地拉罗司及其铁络合物在大鼠体内的药代动力学、分布、代谢和排泄
Drug Metab Dispos. 2008 Dec;36(12):2523-38. doi: 10.1124/dmd.108.022962. Epub 2008 Sep 5.
8
MRP2 haplotypes confer differential susceptibility to toxic liver injury.多药耐药相关蛋白2单倍型赋予对中毒性肝损伤的不同易感性。
Pharmacogenet Genomics. 2007 Jun;17(6):403-15. doi: 10.1097/01.fpc.0000236337.41799.b3.
9
Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities.地拉罗司：在出现肾衰竭死亡、粒细胞缺乏症及其他毒性反应后，其未来前景不明。
Expert Opin Drug Saf. 2007 May;6(3):235-9. doi: 10.1517/14740338.6.3.235.
10
Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.药物不良反应的因果关系评估——I. 一种基于国际共识会议结论的新方法：应用于药物性肝损伤
J Clin Epidemiol. 1993 Nov;46(11):1323-30. doi: 10.1016/0895-4356(93)90101-6.